Skip to the content

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

Davidson, EJ, Faulkner, RL, Sehr, P, Pawlita, M, Smyth, LJC, Burt, DJ, Tomlinson, AE, Hickling, J, Kitchener, HC and Stern, PL 2004, 'Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)' , Vaccine, 22 (21-22) , pp. 2722-2729.

Full text not available from this repository. (Request a copy)

Abstract

Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.

Item Type: Article
Themes: Subjects / Themes > Q Science > QR Microbiology
Subjects outside of the University Themes
Schools: Colleges and Schools > College of Science & Technology
Colleges and Schools > College of Science & Technology > School of Environment and Life Sciences
Journal or Publication Title: Vaccine
Publisher: Elsevier
Refereed: Yes
ISSN: 0264410X
Depositing User: Users 29196 not found.
Date Deposited: 23 Dec 2010 14:37
Last Modified: 20 Aug 2013 17:44
URI: http://usir.salford.ac.uk/id/eprint/12689

Actions (login required)

Edit record (repository staff only)